Zoldonrasib in Patients With <em>KRAS</em> G12D–Mutant NSCLC Previously Treated With Chemoimmunotherapy - Takeaways - MDSpire
Clinical Guidelines
Feature

Zoldonrasib in Patients With <em>KRAS</em> G12D–Mutant NSCLC Previously Treated With Chemoimmunotherapy

The investigational KRAS G12D inhibitor zoldonrasib had a favorable safety profile and induced antitumor activity in some patients with KRAS G12D–mutated non–small cell lung cancer (NSCLC) who were pr...

Share

  • 1

    Zoldonrasib targets KRAS G12D mutations in NSCLC.

  • 2

    Achieved a 52% objective response rate in patients.

  • 3

    Patients followed for a median of 13.1 months.

  • 4

    Common side effects included nausea (43%) and diarrhea (30%).

  • 5

    Breakthrough Therapy designation received from FDA.

  • 6

    Study indicates promising safety and efficacy.

  • 7

    Encourages further research into KRAS G12D treatments.

Original Source(s)

Zoldonrasib in Patients With <em>KRAS</em> G12D–Mutant NSCLC Previously Treated With Chemoimmunotherapy

  • by The ASCO Post Staff

  • May 4, 2026

Related Content

This Week’s Biopharma News: EU Clears First Pertuzumab Biosimilar

Plus: NICE backs rozanolixizumab for uncontrolled gMG, Genexine reports SOX2 degrader data, and BeOne secures option on Huahui trispecific antibody

  • May 5, 2026

  • 5 min
COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings

Patients diagnosed with metastatic breast cancer and non–small cell lung cancer had longer survival compared to national benchmarks when treated in independent community oncology practices, according ...

Early-Onset ICI-Related Myocarditis Linked to Increased Mortality

Early-onset of immune checkpoint inhibitor (ICI)-related myocarditis was associated with an increased risk for myocarditis fatality, according to the results of a study presented at the American Assoc...